Azer Cell Toxicity from Ken, page-4

Looks like the Professor's opinion is the best we will get as IMU is again, strangely, sending the CFO into the "trenches":

"The patients’ data presented by Dr. Shah in April, 2024 at the IW CART conference reflects enrolment by Precision Biosciences prior to Imugene’s acquisition and reflects Phase 1 trial data.

Following successful completion of the Phase 1 trial, clinical development has progressed and Imugene is currently conducting a Phase 1b trial.

We refer you to previous disclosures, in particular the IMU corporate presentations in August 2023 (Page 7 Executive Summary) in which it was stated, inter alia, that the drug has “Demonstrated Safety……..”.

There is no variance to that statement required.

We remain compliant with our continuous disclosure obligations. We are unable to respond to private emails on matters which have not been disclosed in the public domain.

Regards

Mike Tonroe

Chief Financial Officer